We bring you the latest news from the healthcare about the health care in the United Kingdom.

vrijdag 27 oktober 2017

The Lancet: [Articles] Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patien...

[Articles] Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial
The study met the primary endpoint in all three treatment groups. Safety profiles were consistent with the known safety profiles of these agents. Further studies are needed to confirm the antitumour efficacy of the combination of a somatostatin analogue with everolimus in lung and thymic carcinoids.
Read more

[Comment] Towards personalised medicine in lung and thymus neuroendocrine tumours
A personalised treatment approach is increasingly the aim of oncology care. In the gastrointestinal tract, an effective grading system has been devised for neuroendocrine tumours to guide treatment strategies and help malignancy stratification, but for lung and thymus carcinoids this information has remained less reliable, especially in metastatic tumours where diagnostic material is limited and for cases with similar histology.1
Read more

[Comment] and rearrangement in NSCLC: rapidly evolving standards
Approximately 5% of patients with non-small-cell lung cancer (NSCLC) have a rearrangement in the gene for anaplastic lymphoma kinase (ALK), an oncogenic fusion protein.1 Crizotinib, alectinib, and ceritinib are tyrosine kinase inhibitors (TKIs) used for untreated, ALK-positive patients. Crizotinib was approved as frontline therapy based on results showing longer progression-free survival (10·9 months [95% CI 8·3–13·9]) than that seen with platinum-based chemotherapy (7·0 months [95% CI 6·8–8·2]; hazard ratio [HR] for progression or death 0·45, 95% CI 0·35–0·60; p<0·001).
Read more

[Articles] Lorlatinib in non-small-cell lung cancer with or rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial
In this phase 1, dose-escalation study, lorlatinib showed both systemic and intracranial activity in patients with advanced ALK-positive or ROS1-positive NSCLC, most of whom had CNS metastases and had previously had two or more TKI treatments fail. Therefore, lorlatinib might be an effective therapeutic strategy for patients with ALK-positive NSCLC who have become resistant to currently available TKIs, including second-generation ALK TKIs, and is being investigated in a phase 3 randomised controlled trial comparing lorlatinib to crizotinib (ClinicalTrials.gov, NCT03052608).
Read more

[News] Carcinogenicity of benzene
In October, 2017, a Working Group of 27 scientists from 13 countries met at the International Agency for Research on Cancer (IARC) in Lyon, France, to finalise their evaluation of the carcinogenicity of benzene. This assessment will be published in Volume 120 of the IARC Monographs.1
Read more